Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yohei Doi

Showing results (441-450 of 494) with videos related to

Pageof 50
Sort By:
Microorganisms|March 27, 2025
Safety and Efficacy of Ephedrine Alkaloids-Free Ephedra Herb Extract (EFE) for Mild COVID-19: A Double-Blind, Placebo-Controlled, Randomized Comparative TrialHiroshi Odaguchi, Sumiko Hyuga, Mariko Sekine, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2024
Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infectionsAngelique E Boutzoukas, Natalie Mackow, Abhigya Giri, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2024
<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitalsAlina Iovleva, Christi L McElheny, Erin L Fowler, et al.
The Journal of Antimicrobial Chemotherapy|July 28, 2018
Proposal for assignment of allele numbers for mobile colistin resistance (mcr) genesSally R Partridge, Vincenzo Di Pilato, Yohei Doi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2021
Antibacterial Resistance Leadership Group 2.0: Back to BusinessHenry F Chambers, Scott R Evans, Robin Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2023
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership GroupMichael J Satlin, David van Duin, Pranita D Tamma, et al.
Infectious Diseases and Therapy|March 21, 2022
Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry JapanShinya Tsuzuki, Kayoko Hayakawa, Yohei Doi, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2023
High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variantWilliam C Shropshire, Bradley T Endres, Jovan Borjan, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 12, 2026
Matching-adjusted comparison of the effectiveness and safety of Ensitrelvir versus Remdesivir for high-risk, hospitalized patients with non-severe COVID-19 in JapanYoshikazu Mutoh, Toshiyuki Yamaguchi, Koki Sakurai, et al.
The Lancet. Infectious Diseases|November 26, 2015
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological studyYi-Yun Liu, Yang Wang, Timothy R Walsh, et al.
Pageof 50

Showing results (441-450 of 494) with videos related to

Sort By:
Pageof 50
Microorganisms|March 27, 2025
Safety and Efficacy of Ephedrine Alkaloids-Free Ephedra Herb Extract (EFE) for Mild COVID-19: A Double-Blind, Placebo-Controlled, Randomized Comparative TrialHiroshi Odaguchi, Sumiko Hyuga, Mariko Sekine, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2024
Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infectionsAngelique E Boutzoukas, Natalie Mackow, Abhigya Giri, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2024
<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitalsAlina Iovleva, Christi L McElheny, Erin L Fowler, et al.
The Journal of Antimicrobial Chemotherapy|July 28, 2018
Proposal for assignment of allele numbers for mobile colistin resistance (mcr) genesSally R Partridge, Vincenzo Di Pilato, Yohei Doi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2021
Antibacterial Resistance Leadership Group 2.0: Back to BusinessHenry F Chambers, Scott R Evans, Robin Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2023
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership GroupMichael J Satlin, David van Duin, Pranita D Tamma, et al.
Infectious Diseases and Therapy|March 21, 2022
Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry JapanShinya Tsuzuki, Kayoko Hayakawa, Yohei Doi, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2023
High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variantWilliam C Shropshire, Bradley T Endres, Jovan Borjan, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 12, 2026
Matching-adjusted comparison of the effectiveness and safety of Ensitrelvir versus Remdesivir for high-risk, hospitalized patients with non-severe COVID-19 in JapanYoshikazu Mutoh, Toshiyuki Yamaguchi, Koki Sakurai, et al.
The Lancet. Infectious Diseases|November 26, 2015
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological studyYi-Yun Liu, Yang Wang, Timothy R Walsh, et al.
Pageof 50